연구성과로 돌아가기

2023 연구자 정보 (139 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Cho, Young Youn
(Cho, YY) ⓘ 		Chung Ang Univ Hosp, Seoul, South Korea
Chung Ang Univ Hosp, Dept Internal Med, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] PROPOSAL OF A NOVEL SEROLOGICAL ALGORITHM COMBINING A FIBROSIS INDEX BASED ON FOUR AND SERUM MAC-2 BINDING PROTEIN GLYCOSYLATION ISOMER FOR ADVANCED FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE
[JCR상위 1.7] The role of M2BPGi in screening for advanced hepatic fibrosis in diabetic patients
[JCR상위 1.7] The role of M2BPGi for screening of advanced hepatic fibrosis in elderly patients
[JCR상위 1.7] Fibrosis-4 and M2BPGi combination screening algorithm for screening advanced hepatic fibrosis in diabetes is cost-effective
[JCR상위 1.7] Diagnostic efficacy of Mac-2 binding protein glycosylation isomer for predicting liver fibrosis in patients with metabolic associated fatty liver disease: multicenter cohort study
[JCR상위 24.1] Inverse Propensity Score-Weighted Analysis of Entecavir and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B: A Large-Scale Multicenter Study ⓘ 		SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY
ONCOLOGY ⓘ 		noshin@hanyang.ac.kr;
gongori1004@gmail.com;
yoonjun@snu.ac.kr; ⓘ
Choe, Byung Ho
(Choe, BH) ⓘ 		Kyungpook Natl Univ, Sch Med, Daegu, South Korea
Kyungpook Natl Univ Childrens Hosp, Daegu, South Korea ⓘ 		KSM-6251-2024
Choe, Byung-Ho ⓘ 		0000-0001-9899-9120
Choe, Byung-Ho ⓘ 		[JCR상위 4.5] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 2 YEARS IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B ( CHB) ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Chuang, Wan-Long
(Chuang, WL) ⓘ 		Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hepatobiliary Sect, Dept Internal Med, Kaohsiung, Taiwan ⓘ C-9536-2009
Chuang, Wan-Long ⓘ
ⓘ 		[JCR상위 4.5] PHASE 1b/2a STUDY OF HETEROLOGOUS ChAdOx1-HBV/MVA-HBV THERAPEUTIC VACCINATION (VTP-300) COMBINED WITH LOW-DOSE NIVOLUMAB (LDN) IN VIRALLY-SUPPRESSED PATIENTS WITH CHB ON NUCLEOS(T)IDE ANALOGUES ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Chung, Woo Jin
(Chung, WJ) ⓘ 		Keimyung Univ, Sch Med, Daegu, South Korea
Keimyung Univ, Dongsan Hosp, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] REAL-WORLD EXPERIENCE OF ATEZOLIZUMAB PLUS BEVACIZUMAB COMBINATION TREATMENT IN HIGH-RISK PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
[JCR상위 1.7] Real-world experience of atezolizumab plus bevacizumab combination treatment in high risk patients with advanced hepatocellular carcinoma
[JCR상위 4.5] AN ARTIFICIAL INTELLIGENCE MODEL FOR PREDICTION OF HEPATOCELLULAR CARCINOMA DEVELOPMENT AFTER ORAL ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C☆
[JCR상위 4.5] HCC PREDICTION MODELS EFFECTIVELY ASSESS THE RISK OF HCC IN CHRONIC HEPATITIS C PATIENTS WITHOUT ADVANCED FIBROSIS AFTER ORAL ANTIVIRAL THERAPY: A MULTICENTER STUDY ⓘ 		SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ jheo@pusan.ac.kr; ⓘ
Cremer, Ji Won
(Cremer, JW) ⓘ 		GSK, Durham, NC USA ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Diaconescu, Gheorghe Iulian
(Diaconescu, GI) ⓘ 		Spitalul Clin Boli Infectioase Si Pneumoftiziol V, Craiova, Romania ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Elston, Robert
(Elston, R) ⓘ 		GSK, Stevenage, Herts, England ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY
[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report ⓘ 		SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ robert.c.elston@gsk.com; ⓘ
Evans, Tom
(Evans, T) ⓘ 		Vaccitech, Clin Operat, Oxford, England ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] PHASE 1b/2a STUDY OF HETEROLOGOUS ChAdOx1-HBV/MVA-HBV THERAPEUTIC VACCINATION (VTP-300) COMBINED WITH LOW-DOSE NIVOLUMAB (LDN) IN VIRALLY-SUPPRESSED PATIENTS WITH CHB ON NUCLEOS(T)IDE ANALOGUES ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Flaherty, John F.
(Flaherty, JF) ⓘ 		Gilead Sci Inc, Foster City, CA USA ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 2 YEARS IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B ( CHB) ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Fujiyama, Shigetoshi
(Fujiyama, S) ⓘ 		Kumamoto Shinto Gen Hosp, Kumamoto, Japan
Nippon Med Sch, Tokyo, Japan ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY
[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report ⓘ 		SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ robert.c.elston@gsk.com; ⓘ
Furuta, Koichiro
(Furuta, K) ⓘ 		Masuda Red Cross Hosp, Dept Gastroenterol, Masuda, Shimane, Japan ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ daniel_huang@nus.edu.sg;nobuharu.tamaki@gmail.com;psyoung0419@gmail.com;kurosaki@musashino.jrc.or.jp;h.marusawa@osaka-med.jrc.or.jp;matoshi@matsuyama.jrc.or.jp;Masachan44@gmail.com;laboratory@matsue.jrc.or.jp;kobashi0584@gmail.com;furuta-k@masuda.jrc.or.jp;izumi012@musashino.jrc.or.jp;beomkkim@yuhs.ac;sinndhn@hanmail.net; ⓘ
Gadano, Adrian
(Gadano, A) ⓘ 		Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
Hosp Italiano Buenos Aires, Buenos Aires, Argentina ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY
[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report ⓘ 		SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ robert.c.elston@gsk.com; ⓘ
Gankina, Natalia
(Gankina, N) ⓘ 		Krasnojarsk Reg Ctr AIDS Prevent, Krasnoyarsk, Russia ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Han, Sang-Bae
(Han, SB) ⓘ 		Chungbuk Natl Univ, Cheongju, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] ALPHA-1 ANTITRYPSIN/ PROTEINASE 3 IMBALANCE EXERTS PROTEOLYTIC REGULATION ON INTERLEUKIN-32 GAMMA TO PROMOTE NONALCOHOLIC STEATOHEPATITIS ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Heo, Jeong
(Heo, J) ⓘ 		Pusan Natl Univ, Coll Med, Dept Internal Med, Busan, South Korea
Pusan Natl Univ Hosp, Busan, South Korea
Pusan Natl Univ, Dept Internal Med, Coll Med, Busan, South Korea
Middlemore Hosp, Dept Gastroenterol & Hepatol, Auckland, New Zealand
Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea
Pusan Natl Univ, Coll Med, Busan, Peoples R China ⓘ 		MHQ-1390-2025
Heo, Jeong ⓘ 		0000-0003-0961-7851
Heo, Jeong ⓘ 		[JCR상위 4.5] REAL-WORLD EXPERIENCE OF ATEZOLIZUMAB PLUS BEVACIZUMAB COMBINATION TREATMENT IN HIGH-RISK PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
[JCR상위 1.7] Real-world experience of atezolizumab plus bevacizumab combination treatment in high risk patients with advanced hepatocellular carcinoma
[JCR상위 4.5] AN ARTIFICIAL INTELLIGENCE MODEL FOR PREDICTION OF HEPATOCELLULAR CARCINOMA DEVELOPMENT AFTER ORAL ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C☆
[JCR상위 4.5] HCC PREDICTION MODELS EFFECTIVELY ASSESS THE RISK OF HCC IN CHRONIC HEPATITIS C PATIENTS WITHOUT ADVANCED FIBROSIS AFTER ORAL ANTIVIRAL THERAPY: A MULTICENTER STUDY
[JCR상위 1.7] Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up
[JCR상위 8.7] Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial A Validation Study of 2021 AASLD Practice Guidance for SBP
[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY
[JCR상위 1.7] A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
[JCR상위 0.2] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial
[JCR상위 28.1] Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study ⓘ 		SCIE ⓘ 0.2 GASTROENTEROLOGY & HEPATOLOGY
MEDICINE, GENERAL & INTERNAL ⓘ 		jheo@pusan.ac.kr;
mfyuen@hku.hk;
lacid@korea.ac.kr;mothpickle@naver.com;eug203@naver.com;free93cool@gmail.com;drseo@korea.ac.kr;shkang0114@gmail.com;drkimmy@yonsei.ac.kr;baiksk@yonsei.ac.kr;khskhs@sch.ac.kr;liverkys@schmc.ac.kr;psyoung0419@gmail.com;bik.kim@samsung.com;DRPJY@yuhs.ac;jheo@pusan.ac.kr;sonjh@hanyang.ac.kr;H00175@paik.ac.kr;gihankhys@yuhs.ac;umsh@korea.ac.kr;gudwns21@korea.ac.kr;
pierce.chow@duke-nus.edu.sg;
AHNSH@yuhs.ac;limys@amc.seoul.kr; ⓘ
페이지 이동: